deltatrials
Terminated PHASE3 NCT00037687

Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis

A Phase 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase®) for Reducing 28 Day All Cause Mortality in Patients With Severe Sepsis

Sponsor: ICOS Corporation

Conditions Sepsis
Interventions rPAF-AH
Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Apr 30, 2001 Completion: Dec 31, 2004

A PHASE3 clinical study on Sepsis, this trial is terminated or withdrawn. The trial is conducted by ICOS Corporation and has accumulated 5 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ICOS Corporation
  • Suntory Pharmaceutical
Data source: ICOS Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bothell, United States